Pacific Biosciences of California (PACB) closed at $1.54 in the latest trading session, marking a -6.1% move from the prior day. This change lagged the S&P 500's daily loss of 0.3%. Elsewhere, the Dow saw a downswing of 0.46%, while the tech-heavy Nasdaq depreciated by 0.38%. Heading into today, shares of the maker of genetic analysis technology had gained 32.26% over the past month, outpacing the Medical sector's gain of 0.76% and the S&P 500's gain of 3.64%.Investors will be eagerly watching for the perfo ...

Group 1 - Acadia Realty Trust reported quarterly funds from operations (FFO) of $0.32 per share, missing the Zacks Consensus Estimate of $0.33 per share, but showing an increase from $0.31 per share a year ago, resulting in an FFO surprise of -3.03% [1] - The company posted revenues of $100.59 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.17%, compared to year-ago revenues of $87.25 million, and has topped consensus revenue estimates three times over the last four quarters [2] - The stock has underperformed the market, losing about 23% since the beginning of the year, while the S&P 500 gained 8.6% [3] Group 2 - The current consensus FFO estimate for the coming quarter is $0.34 on revenues of $101.2 million, and for the current fiscal year, it is $1.36 on revenues of $399.8 million [7] - The Zacks Industry Rank for REIT and Equity Trust - Retail is currently in the top 38% of over 250 Zacks industries, indicating that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Navios Maritime Partners LP (NMM) closed at $42.42 in the latest trading session, marking a -1.07% move from the prior day. This move lagged the S&P 500's daily loss of 0.3%. Meanwhile, the Dow experienced a drop of 0.46%, and the technology-dominated Nasdaq saw a decrease of 0.38%. The company's shares have seen an increase of 13.8% over the last month, surpassing the Transportation sector's gain of 2.69% and the S&P 500's gain of 3.64%.Market participants will be closely following the financial results of ...

Kadant (KAI) came out with quarterly earnings of $2.31 per share, beating the Zacks Consensus Estimate of $1.94 per share. This compares to earnings of $2.81 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +19.07%. A quarter ago, it was expected that this equipment supplier for the papermaking and paper recycling industries would post earnings of $1.97 per share when it actually produced earnings of $2.1, delivering a surprise ...

InvenTrust Properties Corp. (IVT) came out with quarterly funds from operations (FFO) of $0.44 per share, missing the Zacks Consensus Estimate of $0.45 per share. This compares to FFO of $0.43 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an FFO surprise of -2.22%. A quarter ago, it was expected that this company would post FFO of $0.46 per share when it actually produced FFO of $0.46, delivering no surprise.Over the last four quarters, the company ...

Group 1 - Adma Biologics (ADMA) closed at $18.26, reflecting a +1.44% change from the previous day, outperforming the S&P 500's loss of 0.3% [1] - Over the past month, ADMA shares have decreased by 1.15%, underperforming the Medical sector's gain of 0.76% and the S&P 500's gain of 3.64% [1] Group 2 - The upcoming financial results for Adma Biologics are anticipated to show an EPS of $0.14, representing a 7.69% increase from the same quarter last year, with quarterly revenue expected to be $121.1 million, up 12.98% year-over-year [2] - Full-year Zacks Consensus Estimates predict earnings of $0.61 per share and revenue of $505.8 million, indicating year-over-year changes of +24.49% and +18.61%, respectively [3] Group 3 - Recent modifications to analyst estimates for Adma Biologics reflect short-term business trends, with positive revisions indicating analyst optimism about the company's profitability [4] - The Zacks Rank system, which integrates estimate changes, currently ranks Adma Biologics at 4 (Sell), with the consensus EPS estimate remaining unchanged over the past month [5][6] Group 4 - Adma Biologics has a Forward P/E ratio of 29.51, which is higher than the industry average of 20.15, suggesting that the company is trading at a premium [7] - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 92, placing it in the top 38% of over 250 industries [7][8]

Company Performance - Broadwind Energy, Inc. (BWEN) closed at $2.87, reflecting a +2.5% increase from the previous day, outperforming the S&P 500's daily loss of 0.3% [1] - Prior to the latest trading session, shares of Broadwind Energy had gained 54.7%, significantly exceeding the Industrial Products sector's gain of 6.17% and the S&P 500's gain of 3.64% [1] Upcoming Earnings - The company is expected to report an EPS of $0.02, indicating stability compared to the same quarter of the previous year [2] - Revenue is anticipated to be $38.02 million, representing a 4.31% increase compared to the year-ago quarter [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at $0.08 per share, reflecting a +60% change from the prior year [3] - Revenue for the fiscal year is estimated at $151.29 million, indicating a +5.7% change from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Broadwind Energy reflect evolving short-term business trends, with positive revisions indicating analysts' confidence in the company's performance [4] - Adjustments in estimates are associated with imminent stock price performance, and the Zacks Rank system is designed to capitalize on this phenomenon [5] Zacks Rank and Valuation - Broadwind Energy currently holds a Zacks Rank of 1 (Strong Buy), with an impressive track record of outperformance [6] - The company has a Forward P/E ratio of 35, which is a premium compared to the industry average Forward P/E of 21.94 [7] Industry Context - The Manufacturing - General Industrial industry, part of the Industrial Products sector, has a Zacks Industry Rank of 27, placing it in the top 11% of all industries [7] - The strength of individual industry groups is measured by the Zacks Industry Rank, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [8]

Company Overview - Eli Lilly (LLY) closed at $762.95, reflecting a -5.59% change from the previous day, which is worse than the S&P 500's daily loss of 0.3% [1] - Over the last month, Eli Lilly's shares increased by 3.67%, outperforming the Medical sector's gain of 0.76% and the S&P 500's gain of 3.64% [1] Upcoming Earnings - The upcoming earnings report for Eli Lilly is expected on August 7, 2025, with an anticipated EPS of $5.61, representing a 43.11% increase year-over-year [2] - Revenue is forecasted to be $14.75 billion, indicating a 30.49% growth compared to the same quarter of the previous year [2] Full Year Projections - For the full year, Zacks Consensus Estimates project earnings of $22.05 per share and revenue of $60.55 billion, reflecting increases of +69.75% and +34.43% respectively from the prior year [3] - Recent changes to analyst estimates for Eli Lilly are noted as indicators of optimism regarding the business outlook [3] Stock Performance and Valuation - The Zacks Rank system, which assesses estimate changes, indicates that Eli Lilly currently holds a Zacks Rank of 3 (Hold) [5] - The Zacks Consensus EPS estimate has increased by 0.48% in the past month [5] - Eli Lilly's Forward P/E ratio is 36.64, which is a premium compared to its industry's Forward P/E of 14.23 [5] Industry Context - Eli Lilly operates within the Large Cap Pharmaceuticals industry, which has a Zacks Industry Rank of 62, placing it in the top 26% of over 250 industries [7] - The average PEG ratio for the Large Cap Pharmaceuticals industry is 1.24, while Eli Lilly's PEG ratio is 1.15 [6]

BrightSpire (BRSP) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +12.50%. A quarter ago, it was expected that this real estate investment trust would post earnings of $0.16 per share when it actually produced earnings of $0.16, delivering no surprise.Over the last four quarters, the ...

Group 1 - Petrobras (PBR) closed at $12.84, with a daily increase of +2.31%, outperforming the S&P 500's loss of 0.3% [1] - Over the past month, Petrobras shares have appreciated by 0.32%, underperforming the Oils-Energy sector's gain of 3.2% and the S&P 500's gain of 3.64% [1] Group 2 - Analysts expect Petrobras to report earnings of $0.64 per share, reflecting a year-over-year growth of 36.17%, while revenue is projected at $20.25 billion, down 13.73% from the previous year [2] - For the full year, earnings are projected at $2.72 per share and revenue at $81.97 billion, indicating declines of -8.72% and -10.33% respectively from the prior year [3] Group 3 - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), indicates Petrobras currently holds a Zacks Rank of 3 (Hold) [5] - Petrobras has a Forward P/E ratio of 4.62, which is a discount compared to its industry's Forward P/E of 11.46 [5] Group 4 - The Oil and Gas - Integrated - International industry, part of the Oils-Energy sector, has a Zacks Industry Rank of 162, placing it in the bottom 35% of over 250 industries [6] - The Zacks Industry Rank assesses the strength of industry groups based on the average Zacks Rank of individual stocks, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [6]